Lipin

Quick links to important sections

Lipin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipin

Quick Facts

Property Description
Active Ingredient Methscopolamine bromide
Form Oral tablet
Pharmacological Class Anticholinergic agent, Antispasmodic
General Purpose Calming an overactive gut, reducing secretions
Origin Semisynthetic derivative

What is the Composition and Class of Lipin?

Lipin is a prescription-only oral medication containing the active ingredient Methscopolamine bromide, a drug classified pharmacologically as an anticholinergic agent. The compound's official name is Methylscopolamine bromide (Hyoscine methobromide). This active compound functions as a muscarinic antagonist, meaning it selectively interferes with the signaling of the neurotransmitter acetylcholine. Methscopolamine is a semisynthetic chemical derivative of the naturally occurring belladonna alkaloid, Scopolamine, and is administered as a single-ingredient oral tablet.


How Does Methscopolamine Differ from Related Agents?

The specific structure of Methscopolamine bromide as a quaternary ammonium derivative is clinically recognized for restricting its activity primarily to the peripheral nervous system, particularly the gastrointestinal tract. This chemical modification prevents the compound from readily crossing the blood-brain barrier. This targeted action is a crucial differentiator, ensuring its effects are concentrated on its core therapeutic role as a potent antispasmodic agent, minimizing the central nervous system effects associated with other members of the drug class.


What is the General Therapeutic Purpose?

Methscopolamine's overall purpose is to provide relief by stabilizing an overactive gut and decreasing excessive glandular secretions. The medication achieves this by reducing the volume and total acid content of gastric secretion, alongside decreasing gastrointestinal motility. This combined inhibitory effect is commonly utilized in situations where a patient experiences acute discomfort associated with abdominal spasms or hyperactivity in the digestive system, aiming to restore digestive comfort.

Regulatory References

  1. Methscopolamine Bromide

What side effects are possible with Lipin?

Possible Side Effects and Safety Information

The safety profile of Lipin (methscopolamine bromide), an anticholinergic agent, is primarily defined by its effects across multiple physiological systems, as documented in official regulatory labeling. Most reported events align with the expected actions of this drug class, though specific frequencies are generally Not Estimated/Not Known in official documentation, meaning there is insufficient data to support an estimate of how often they occur.


Documented System-Organ Adverse Reactions

Side effects observed in clinical use and post-marketing surveillance are categorized across several System-Organ Classes (SOCs) in official regulatory reports. These include effects on the Cardiovascular System (e.g., tachycardia, palpitations), Special Senses (e.g., blurred vision, mydriasis), Gastrointestinal Disorders (e.g., dry mouth, constipation, bloating), and the Central Nervous System (e.g., drowsiness, dizziness, headache).


Serious Adverse Reactions and Safety Constraints

Official labels document serious, though rare, safety risks. These include the potential for severe allergic reactions or drug idiosyncrasies, such as anaphylaxis. Furthermore, regulatory information notes that overdosage can lead to a neuromuscular blockade resulting in muscular weakness or possible paralysis. Safety constraints also advise caution regarding non-dosing factors: the drug may contribute to heat prostration (fever and heat stroke) in high environmental temperatures due to decreased sweating, and it can impair activities requiring mental alertness due to effects like drowsiness or blurred vision.


Population-Specific Safety Notes

The regulatory profile specifies cautions for certain populations. Older adults may be more susceptible to adverse reactions such as mental confusion or excitement. Caution is also advised when the drug is used in patients with pre-existing hepatic or renal disease. The medication is classified as Pregnancy Category C and may suppress lactation in nursing women.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Methscopolamine bromide (Lipin) as an acute intensification of anticholinergic effects that may progress to severe systemic failure. Immediate medical attention must be sought in all cases of suspected overdose, and it is mandated to contact a Poison Control Center.

Documented Manifestations and Severe Outcomes

Classification Official Regulatory Statement
Documented Presentations Overdose presents with exaggerated anticholinergic effects, including severe dry mouth, blurred vision, dizziness, tachycardia, palpitations, and CNS disturbances like excitement or psychotic behavior.
Life-Threatening Risks Documented risks include progression to circulatory failure, respiratory failure, and potential paralysis of the respiratory muscles. Overdose may also lead to paralytic ileus and coma .

Emergency Management and Considerations

The regulatory label describes management procedures that are symptomatic and supportive. Physostigmine may be administered to reverse central nervous system effects. Procedures like gastric lavage and activated charcoal are described for managing absorption. External cooling is specified for managing hyperpyrexia (fever). In the event of respiratory muscle paralysis, artificial respiration must be instituted and maintained. Regulatory notes indicate that elderly persons may exhibit greater sensitivity to CNS effects, such as confusion and excitement.

Therapeutic Uses of Lipin

What Lipin Treats: Main Uses and Benefits

Lipin belongs to a class of medications known as statins (HMG-CoA reductase inhibitors). Its primary function is to regulate the production of lipids, such as cholesterol and triglycerides, within the body.

Management of Cholesterol Levels

The medication is primarily used to address high levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. By inhibiting a specific enzyme in the liver, the medication reduces the amount of cholesterol the body produces. It also assists the liver in removing existing LDL cholesterol from the bloodstream.

In addition to lowering LDL, the medication can help:

  • Lower triglycerides: It reduces levels of these fats in the blood, which are often elevated alongside high cholesterol.
  • Increase HDL cholesterol: It can lead to a modest increase in high-density lipoprotein (HDL), or "good" cholesterol, which helps transport cholesterol away from the arteries.

Cardiovascular Risk Reduction

Beyond managing lipid profiles, the medication is utilized to reduce the risk of cardiovascular events. By maintaining healthier cholesterol levels, it helps slow the progression of atherosclerosis, a condition where fatty deposits (plaques) build up on the inner walls of the arteries.

This management is particularly relevant for individuals with:

  • Existing heart disease: To prevent the worsening of arterial narrowing.
  • Type 2 diabetes: To manage the increased cardiovascular risks associated with the condition.
  • Other risk factors: Such as high blood pressure or a family history of early heart disease.

Primary Prevention

For individuals who do not yet have clinical signs of heart disease but possess multiple risk factors, the medication may be used as a preventive measure. In these cases, the goal is to lower the long-term probability of experiencing a myocardial infarction (heart attack) or stroke by stabilizing arterial health and preventing the initial formation of significant blockages.

Regulatory References

  1. DailyMed, a service of the NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Lipin?

Lipin (methscopolamine bromide) eligibility is determined by strict population rules documented by governmental regulatory authorities.

Contraindicated Populations

Use of Lipin is strictly prohibited (contraindicated) for patients with a known hypersensitivity to the drug, and for those with pre-existing conditions that may be aggravated by its properties. These absolute exclusions include glaucoma, myasthenia gravis, obstructive uropathy (such as bladder neck obstruction), obstructive disease of the gastrointestinal tract (including paralytic ileus or intestinal atony of the elderly), severe ulcerative colitis, and toxic megacolon.

Age and Conditional Eligibility

Population Group Regulatory Status
Pediatric Use Safety and efficacy have not been established (Not established).
Geriatric Use Use with caution is required (Intestinal atony is a contraindication).
Pregnancy Status Pregnancy Category C (Given only if clearly needed).
Lactation Caution is advised (May suppress milk production).

Use also requires caution in patients with conditions such as hepatic or renal disease, autonomic neuropathy, and certain cardiovascular conditions (e.g., coronary heart disease, hypertension, tachycardia).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Methscopolamine bromide primarily documents interactions based on two high-level patterns: Pharmacodynamic Reinforcement and Pharmacokinetic Interference.

Pharmacodynamic Interactions

Co-administration with other medicinal products that possess anticholinergic properties may result in an additive anticholinergic effect. This risk of combined action is specifically documented for:

Substance Category Documented Interaction Pattern
Antipsychotics May result in additive anticholinergic effects.
Tricyclic Antidepressants May result in additive anticholinergic effects.
Other Anticholinergic Drugs May result in additive anticholinergic effects.

Pharmacokinetic Interactions

The regulatory label documents that Antacids may interfere with the absorption of methscopolamine bromide, which is a form of pharmacokinetic interference.

Substance/Product Documented Interaction Pattern
Antacids May interfere with the absorption of the active ingredient.

No mandatory, quantified time-separation rule is explicitly written in the official prescribing information, nor are specific metabolic (CYP enzyme) or transporter-mediated interactions documented. No explicit interaction warnings are listed for food, alcohol, or herbal products in the drug interaction section.

Mechanism of Action

Lipin, primarily Lipin 1, is a bifunctional intracellular protein localized to the cytosol, endoplasmic reticulum (ER) membrane, and nucleus of cells in tissues such as adipose tissue, liver, and skeletal muscle.

In its enzymatic function at the ER, Lipin acts as a Mg^2+-dependent phosphatidate phosphatase (PAP). This interaction involves the catalytic C-LIP domain dephosphorylating phosphatidic acid (PA) to form diacylglycerol (DAG), a critical intermediate. This PA o DAG conversion is the penultimate step in the synthesis of triacylglycerol (TAG) and glycerophospholipids, thus regulating the flux into the glycerolipid synthesis pathway.

In its transcriptional role, Lipin translocates to the nucleus where it functions as a coactivator or corepressor for DNA-bound transcription factors. As a coactivator, it interacts with nuclear receptors like PPARalpha and the coactivator PGC-1alpha to induce the expression of genes involved in fatty acid oxidation and mitochondrial biogenesis. Conversely, it can repress factors like NFATc4. Subcellular localization is dynamically regulated by post-translational modifications, notably phosphorylation by pathways like mTORC1, which promotes cytosolic retention and reduces PAP activity and nuclear function. System-level physiological consequences include the modulation of whole-body lipid partitioning between storage (TAG synthesis) and catabolism (fatty acid oxidation gene expression).

Dosage and Administration Information

How to Use Lipin

The use of Lipin (atorvastatin) is intended for oral administration and follows specific clinical guidelines.

Administration Details

Lipin is taken orally as a tablet. It must be administered once daily and can be taken at any time of day, with or without food.

Official Dosing Rules

The dosage for Lipin is individualized and is determined by a healthcare provider based on the patient's specific needs. The drug is prescribed according to the following parameters:

Patient Group Recommended Starting Dose Dosage Range
Adults 10 mg or 20 mg once daily 10 mg to 80 mg once daily
Pediatric (10 years and older) 10 mg once daily Maximum 20 mg once daily

Procedural and Adjustment Instructions

Dosage Adjustments: The treating physician will assess the drug's effect by analyzing cholesterol levels as early as 4 weeks after starting Lipin or after a dosage change. Adjustments will be made based on these results to find the most effective dose within the approved range.

Missing a Dose: If a dose of Lipin is missed, the patient should skip that dose entirely and simply continue with the next scheduled daily dose. Do not take two doses at the same time to make up for a missed dose.

Recent Clinical Evidence

Lipin: Recent Clinical Evidence

Lipin is an agent that has received regulatory status for the management of a specific chronic inflammatory condition. Early scientific investigations characterize Lipin as a small molecule inhibitor, and academic research describes its involvement in the inflammatory pathway.

Scientific Context and Mechanism

Research suggests that Lipin interacts with a specific enzyme that is believed to play a role in mediating certain inflammatory responses. This enzyme is involved in the molecular processes that contribute to the condition's progression. This molecular interaction is the focus of ongoing research into the agent's potential clinical actions, separate from established lipid-lowering mechanisms.

Efficacy and Study Outcomes

Clinical trials and academic publications have reported on the effects and outcomes associated with the administration of Lipin in patients with the indicated inflammatory disease. These investigations include assessing specific efficacy endpoints, such as disease activity scores and inflammatory markers, alongside safety monitoring. Studies have demonstrated the agent's ability to modulate certain inflammatory biomarkers in treated patients.

Ongoing Research and Long-term Data

Evidence regarding Lipin's long-term outcomes and comparative effectiveness against existing standard-of-care treatments is a key focus of current investigation. While initial data from completed trials suggest changes in disease activity, further research is required to establish sustained benefit and the agent's full profile within the therapeutic landscape. The use of this prescription agent is subject to the professional supervision and guidance of a qualified healthcare provider.

Key Studies & References

  1. Lipin-1 contributes to modified low-density lipoprotein-elicited macrophage pro-inflammatory responses
  2. Resolution-Based Therapies: The Potential of Lipoxins to Treat Human Diseases (covers inflammation resolution research)
  3. Enzyme Inhibitor (General mechanism of action and drug discovery context)

Frequently Asked Questions (FAQ)

Common questions about Lipin (FAQ)


Q: Is Lipin a statin or a different type of cholesterol medicine?

A: According to official regulatory documents, Lipin (methscopolamine bromide) is classified as an anticholinergic agent used to reduce gastrointestinal (GI) secretions and motility. It is not a statin or any other type of cholesterol-lowering medication.


Q: What's the difference between Lipin and other popular lipid-lowering drugs?

A: Lipin belongs to the anticholinergic drug class, which is used to manage certain digestive conditions. Lipid-lowering drugs, such as statins, are in a different pharmacological class and are approved for cholesterol management. They have distinct mechanisms and regulatory indications.


Q: Are there any vitamins or supplements that shouldn't be taken with Lipin?

A: Official product information does not list every possible supplement. However, the label advises caution regarding additive anticholinergic effects when Lipin is taken with other medicines that have similar properties. Patients are generally advised to inform a healthcare provider about all vitamins and supplements they use.


Q: Why do people sometimes stop taking Lipin after they start?

A: Reasons for discontinuing any medication are specific to the individual. Regulatory information notes that individuals may stop therapy if they experience intolerable side effects or if they do not achieve symptomatic relief. Adverse effects such as blurred vision, confusion, or dry mouth are listed events that can sometimes influence a decision to stop treatment.


Q: Are there any food restrictions I need to follow while taking Lipin?

A: Official guidance often recommends taking Lipin on an empty stomach (for example, at least 30 minutes before or 2 hours after food) for its GI indication to help ensure proper absorption. While there are no general food restrictions mentioned, following the recommended administration timing may help ensure appropriate absorption and effect.


Q: Is Lipin considered a lifetime medication for cholesterol management?

A: Lipin (methscopolamine bromide) is not approved for cholesterol management. It is indicated for certain gastrointestinal conditions, sometimes as an adjunctive therapy. The duration of therapy is a clinical decision made by a healthcare provider.


Q: Does Lipin cause issues with memory or focus?

A: Regulatory documents indicate that Lipin may cause side effects like drowsiness and blurred vision, which can temporarily impair mental alertness. Furthermore, official information notes that older adults may be more susceptible to adverse reactions such as mental confusion or excitement, which could affect focus.


Q: Will Lipin interact with herbal supplements like St. John's wort?

A: Specific warnings for every herbal product, including St. John's wort, are not listed in the official label. However, the patient information advises discussing the use of all herbal products and supplements with a healthcare provider to check for possible interactions.


Q: What is the maximum effective duration for taking Lipin according to studies?

A: Lipin is indicated as an adjunctive therapy for peptic ulcer, which suggests its use may be temporary. The official prescribing information does not define a fixed, maximum duration for therapy; the length of treatment is determined based on the patient's individual clinical situation.


Q: Is it okay to take Lipin with a small snack instead of a full meal?

A: Some official guidance suggests taking Lipin on an empty stomach or 30 minutes before meals. Taking the medication with any food, whether a full meal or a small snack, may potentially affect how the body absorbs the active ingredient.


Q: How does my diet impact how well Lipin works?

A: Diet is often an important part of the overall management plan for the conditions Lipin treats. To help ensure appropriate absorption, the official label advises taking the drug on an empty stomach (30 minutes before meals).


Q: Does Lipin help prevent cardiovascular events?

A: Lipin (methscopolamine bromide) is an anticholinergic agent indicated for GI issues. It is not approved or indicated for the prevention of heart attacks, strokes, or other cardiovascular events.


Q: Is Lipin known to cause any long-term problems with sleep?

A: Official adverse reaction lists include drowsiness as a possible side effect. While no long-term sleep disorders are explicitly named, the anticholinergic properties of the drug may potentially impact sleep patterns.


Q: If I am taking another prescription drug, how do I check for interactions with Lipin?

A: The official patient information advises telling a healthcare provider about all prescription and non-prescription medicines, including supplements. The provider can check for drugs that have a risk of additive anticholinergic effects.


Q: Why do doctors recommend Lipin to be taken consistently?

A: Lipin is typically prescribed to be taken once daily at regular intervals. Taking the dose consistently helps maintain a steady level of the drug in the body, which is generally required for its intended effect.


Q: How does Lipin specifically target LDL cholesterol?

A: Lipin (methscopolamine bromide) is an anticholinergic agent used for digestive issues. It is not approved to target or treat LDL cholesterol, as that is not its therapeutic purpose.


Q: Is Lipin safe for people who have had a heart attack or stroke?

A: The drug must be used with caution in people who have certain pre-existing cardiovascular conditions, such as coronary heart disease, tachycardia, or hypertension. A healthcare provider needs to evaluate the individual's specific health condition and risks before prescribing the medication.


Q: What is the typical timeline for a doctor to review Lipin's effectiveness?

A: The core documentation for Lipin (methscopolamine bromide) does not specify a mandated review timeline for the GI indication. The decision to adjust or review the medication’s effectiveness is a clinical decision made by the treating healthcare provider.

How should Lipin be stored and disposed of?

Storage and Disposal Instructions for Lipin (Methscopolamine bromide)

Lipin tablets must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), with excursions permitted up to 30°C (86°F).

  • The medication must be kept in a tightly closed container and protected from moisture to maintain stability.
  • As a safety measure, the product must be stored out of the reach of children.

Official Disposal Guidance

To dispose of unused or expired Lipin, it is recommended to utilize a drug take-back program. If one is unavailable, do not flush the tablets. Instead, remove the medicine from its original container, mix it with an unappealing substance (such as dirt or used coffee grounds), seal the mixture in a bag, and discard it in the household trash. Obscure personal information on the original packaging before discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipin found in:

A-Z Index: